Russell Investments Group Ltd. Has $217.75 Million Holdings in Danaher Corporation (NYSE:DHR)

Russell Investments Group Ltd. raised its position in Danaher Corporation (NYSE:DHR) by 11.4% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,061,970 shares of the conglomerate’s stock after buying an additional 108,696 shares during the period. Russell Investments Group Ltd. owned 0.15% of Danaher worth $217,749,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Danaher by 0.4% during the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate’s stock worth $12,296,123,000 after purchasing an additional 230,966 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Danaher by 2.3% during the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate’s stock worth $1,800,614,000 after purchasing an additional 194,466 shares in the last quarter. Northern Trust Corp lifted its holdings in Danaher by 14.3% in the fourth quarter. Northern Trust Corp now owns 7,934,991 shares of the conglomerate’s stock valued at $1,821,477,000 after buying an additional 992,594 shares during the period. Capital World Investors lifted its holdings in Danaher by 32.7% in the fourth quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate’s stock valued at $1,460,215,000 after buying an additional 1,566,658 shares during the period. Finally, Capital Research Global Investors lifted its holdings in Danaher by 6.8% in the fourth quarter. Capital Research Global Investors now owns 5,812,728 shares of the conglomerate’s stock valued at $1,334,312,000 after buying an additional 370,111 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Down 0.4%

Shares of DHR opened at $199.83 on Tuesday. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.90. The firm has a market cap of $143.09 billion, a P/E ratio of 42.52, a price-to-earnings-growth ratio of 2.80 and a beta of 0.73. The firm’s 50-day simple moving average is $198.68 and its 200 day simple moving average is $200.30. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating analysts’ consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same quarter in the prior year, the business earned $1.72 EPS. Danaher’s quarterly revenue was up 3.4% on a year-over-year basis. On average, analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Bank of America cut their price objective on shares of Danaher from $265.00 to $230.00 in a report on Monday, April 14th. Evercore ISI cut their price objective on shares of Danaher from $230.00 to $226.00 and set an “outperform” rating on the stock in a report on Tuesday, July 8th. HSBC cut their price objective on shares of Danaher from $270.00 to $240.00 in a report on Friday, April 25th. Robert W. Baird upped their target price on shares of Danaher from $225.00 to $226.00 and gave the company an “outperform” rating in a research note on Friday, July 18th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $250.00 target price on shares of Danaher in a research note on Wednesday, April 23rd. Three analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, Danaher has an average rating of “Moderate Buy” and an average target price of $247.61.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.